Metabolic Progressive Subtypes in Progressive Supranuclear Palsy
Objective: To investigate disease-specific spatiotemporal progression in Progressive supranuclear palsy (PSP) patients using 18F-fluorodeoxyglucose (FDG) PET and the Subtype and Stage Inference (SuStaIn) algorithm, to…The Impact of Apathy and Impulsivity on Caregivers in Atypical Parkinsonian Syndromes
Objective: This study aims to investigate the impact of apathy and impulsivity on the quality of life and burden for carergivers of people with Atypical…Nigral Neuroinflammation and Dopaminergic Neurons in PD, MSA and PSP: A Comparative Clinicopathological Study
Objective: To investigate nigral neuroinflammatory markers and dopaminergic neuron counts in parkinsonian disorders, comparing their profiles across conditions. Background: In degenerative parkinsonian disorders, the primary…Decoding non-IPD Parkinsonism – A Comparative Analysis of Atypical and Secondary Parkinsonism
Objective: Using precise diagnostic criteria, the single-center observational study aims to evaluate the clinical profiles of non-IPD parkinsonism, specifically identifying crucial clinical clues for discriminating…ORION: A Global Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of AMX0035 in Progressive Supranuclear Palsy (A35-009)
Objective: Here we describe ORION, a phase 3 trial assessing efficacy and safety of AMX0035 in progressive supranuclear palsy (PSP). Background: PSP is a rare,…Clinical and neuroimaging factors associated with survival in Progressive Supranuclear Palsy
Objective: To assess clinical and neuroimaging factors associated with survival in a cohort of patients with a final clinical diagnosis of Progressive Supranuclear Palsy (PSP)…Metabolic Covariance Networks in Progressive Supranuclear Palsy Revealed by Spatial independent component analysis
Objective: The study aims to apply S-ICA to 18F-fluorodeoxyglucose (FDG) data in progressive supranuclear palsy (PSP) patients, identifing PSP-specific independent metabolic covariate networks. We also…Noradrenaline treatment of apathy and impulsivity in participants with Progressive Supranuclear Palsy syndromes (NORAPS). A Phase II clinical trial – ISRCTN99462035.
Objective: The NORAPS Phase II clinical trial seeks to demonstrate safety, tolerability and efficacy of atomoxetine in Progressive Supranuclear Palsy (PSP). Background: PSP is a…Paraneoplastic neurological syndrome mimicking a progressive supranuclear palsy: a case series
Objective: we describe 2 patients with paraneoplastic parkinsonism mimicking a PSP. Background: Paraneoplastic neurological syndromes (PNS) are broad-spectrum disorders that can affect any part of…Frequency of Falls as a Presenti̇ng Symptom and Its Effect i̇n Prognosi̇s i̇n Progressi̇ve Supranuclear Palsy
Objective: We aimed to evaluate frequency of falls as a presenting symptom and its effect on prognosis in PSP patients. Background: Progressive supranuclear palsy is…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 49
- Next Page »